ACID REDUCER (OMEPRAZOLE MAGNESIUM)
- Duodenal ulcer
- Dyspepsia
- Gastric ulcer
- Gastroesophageal reflux disease
- Heartburn
- Duodenal ulcer
- Duodenal ulcer due to h. pylori
- Dyspepsia prevention
- Erosive esophagitis
- Gastric hypersecretion with systemic mastocytosis
- Gastric ulcer
- Heartburn
- Heartburn prevention
- Helicobacter pylori gastritis
- Maintenance of healing duodenal ulcer
- Maintenance of healing erosive esophagitis
- Multiple endocrine neoplasia
- Pathological gastric acid hypersecretory condition
- Reflux esophagitis
- Zollinger-ellison syndrome
- Pepcid Tablet
- Pepcid Ac Tablet
- Omeprazole Magnesium Capsule,delayed Release
- Heartburn Relief (famotidine) Tablet
- Heartburn Prevention Tablet
- Famotidine Tablet
- Acid Reducer (omeprazole) Capsule,delayed Release
- Acid Reducer (famotidine) Tablet
- Acid Controller Tablet
- By Indication
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
40 mg tablet
- 1 tablet (40 mg) by oral route once daily at bedtime
10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
20 mg capsule,delayed release
- Dosage information is not available
(famotidine) 10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
(famotidine) 20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
40 mg tablet
- 1 tablet (40 mg) by oral route once daily at bedtime
(omeprazole) 20 mg capsule,delayed release
- Dosage information is not available
(famotidine) 10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
(famotidine) 20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
ler 10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
ler 20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
Duodenal ulcer
- 1 tablet (20 mg) by oral route every 12 hours
- 1 tablet (20 mg) by oral route 2 times per day
- 2 tablets (40 mg) by oral route once daily at bedtime
Dyspepsia
- 1 tablet (10 mg) by oral route 2 times per day as needed
- 1 tablet (10 mg) by oral route once daily as needed
- 2 tablets (20 mg) by oral route every 12 hours
Dyspepsia prevention
- 1 tablet (10 mg) by oral route 2 times per day as needed
- 1 tablet (10 mg) by oral route once daily as needed
- 2 tablets (20 mg) by oral route every 12 hours
Erosive esophagitis
- 1 tablet (20 mg) by oral route 2 times per day
- 2 tablets (40 mg) by oral route 2 times per day
Gastric hypersecretion with systemic mastocytosis
- 1 tablet (20 mg) by oral route every 6 hours
- 2 tablets (40 mg) by oral route every 6 hours
Gastric ulcer
- 2 tablets (40 mg) by oral route once daily at bedtime
Gastroesophageal reflux disease
- 1 tablet (20 mg) by oral route every 12 hours
- 1 tablet (20 mg) by oral route 2 times per day
- 2 tablets (40 mg) by oral route once daily at bedtime
Heartburn
- 1 tablet (10 mg) by oral route 2 times per day as needed
- 1 tablet (10 mg) by oral route once daily as needed
Heartburn prevention
- 1 tablet (10 mg) by oral route 2 times per day as needed
- 1 tablet (10 mg) by oral route once daily as needed
Maintenance of healing duodenal ulcer
- 1 tablet (20 mg) by oral route once daily at bedtime
Multiple endocrine neoplasia
- 1 tablet (20 mg) by oral route every 6 hours
- 2 tablets (40 mg) by oral route every 6 hours
Pathological gastric acid hypersecretory condition
- 1 tablet (20 mg) by oral route every 6 hours
- 2 tablets (40 mg) by oral route every 6 hours
Reflux esophagitis
- 1 tablet (20 mg) by oral route 2 times per day
- 2 tablets (40 mg) by oral route 2 times per day
Upper GI bleed
- 1 tablet (20 mg) by oral route every 12 hours
- 1 tablet (20 mg) by oral route 2 times per day
Zollinger-ellison syndrome
- 1 tablet (20 mg) by oral route every 6 hours
- 2 tablets (40 mg) by oral route every 6 hours
- atazanavir
- Complera
- Edurant
- emtricitab-rilpivirine-tenofov
- nelfinavir
- Reyataz
- rilpivirine
- Viracept
Contraindicated
- Bosulif
- bosutinib
- Cellcept
- Cellcept Intravenous
- citalopram
- clobazam
- clopidogrel
- dasatinib
- erlotinib
- itraconazole
- ketoconazole
- methotrexate sodium
- methotrexate sodium (PF)
- mycophenolate mofetil
- mycophenolate mofetil HCl
- nilotinib
- Noxafil
- Onfi
- Onmel
- Plavix
- posaconazole
- Sporanox
- Sporanox Pulsepak
- Sprycel
- Tarceva
- Tasigna
- tizanidine
- Zanaflex
Severe
Moderate
- Adderall
- Adderall Xr
- Amphetamine Salt Combo
- Astagraf Xl
- Ceftin
- cefuroxime axetil
- Celexa
- Cerebyx
- Dexedrine Spansule
- dextroamphetamine
- dextroamphetamine-amphetamine
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- escitalopram oxalate
- ethotoin
- fosphenytoin
- Hecoria
- Isentress
- Lexapro
- Methotrexate (anti-rheumatic)
- Peganone
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Procentra
- Prograf
- raltegravir
- Rheumatrex
- tacrolimus
- Trexall
- Vfend
- Vfend Iv
- voriconazole
- Zenzedi
- None
Contraindicated
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Clostridium difficile infection
- Gastric cancer
- Interstitial nephritis
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
Severe
Moderate
- CYp2c19 poor metabolizer
- Disease of liver
- Fracture
- Hypomagnesemia
- Kidney disease with likely reduction in GFR
- Osteoporosis
- Vitamin b12 deficiency
ACID REDUCER (OMEPRAZOLE MAGNESIUM)
- Duodenal ulcer
- Dyspepsia
- Gastric ulcer
- Gastroesophageal reflux disease
- Heartburn
- Duodenal ulcer
- Duodenal ulcer due to h. pylori
- Dyspepsia prevention
- Erosive esophagitis
- Gastric hypersecretion with systemic mastocytosis
- Gastric ulcer
- Heartburn
- Heartburn prevention
- Helicobacter pylori gastritis
- Maintenance of healing duodenal ulcer
- Maintenance of healing erosive esophagitis
- Multiple endocrine neoplasia
- Pathological gastric acid hypersecretory condition
- Reflux esophagitis
- Zollinger-ellison syndrome
- None
- Acute abdominal pain
- Constipation
- Diarrhea
- Dizziness
- Flatulence
- Headache disorder
- Vomiting
More Frequent
Severe
Less Severe
- None
- Back pain
- Chest pain
- Constipation
- Cough
- Dizziness
- Fever
- General weakness
- Nausea
- Pruritus of skin
- Upper respiratory infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Agranulocytosis
- Anaphylaxis
- Anemia
- Angioedema
- Anterior ischemic optic neuropathy
- Atrioventricular block
- Atrophic gastritis
- Bradycardia
- Bronchospastic pulmonary disease
- Cardiac arrhythmia
- Cholestatic hepatitis
- Clostridium difficile infection
- Dyspnea
- Erythema multiforme
- Esophageal candidiasis
- Fracture
- Hematuria
- Hepatic failure
- Hepatitis
- Hyperbilirubinemia
- Hypoglycemic disorder
- Hyponatremia
- Hypotension
- Increased alanine transaminase
- Increased aspartate transaminase
- Interstitial nephritis
- Interstitial pneumonitis
- Leukocytosis
- Leukopenia
- Neutropenic disorder
- Obstructive hyperbilirubinemia
- Optic neuritis
- Pancreatitis
- Pancytopenia
- Proteinuria
- Psychiatric disorder
- Rhabdomyolysis
- Seizure disorder
- Skin rash
- Stevens-johnson syndrome
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
- Urticaria
Less Severe
- Abdominal distension
- Acne vulgaris
- Acute abdominal pain
- Acute confusion
- Agitation
- Allergic conjunctivitis
- Alopecia
- Anorexia
- Arthralgias
- Benign fundic gland polyposis of stomach
- Blurred vision
- Cramps
- Delirium
- Diplopia
- Discolored feces
- Drowsy
- Dry eye
- Dry skin
- Dysgeusia
- Epistaxis
- Facial edema
- Fatigue
- Fever
- Flushing
- General weakness
- Glycosuria
- Gynecomastia
- Hallucinations
- Hyperhidrosis
- Hypertension
- Hypomagnesemia
- Insomnia
- Irritable bowel syndrome
- Leg pain
- Lethargy
- Malaise
- Muscle weakness
- Myalgias
- Nausea
- Ocular irritation
- Pain
- Palpitations
- Paresthesia
- Peripheral edema
- Petechiae
- Pruritus of skin
- Purpura
- Skin inflammation
- Skin photosensitivity
- Skin rash
- Sleep disorder
- Sore throat
- Stomatitis
- Tachycardia
- Testicular pain
- Tinnitus
- Tremor
- Urinary tract infection
- Vertigo
- Vitamin b12 deficiency
- Vomiting
- Weight gain
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Omeprazole (Oral)
Safety and efficacy not established age less than 1 year.
- 1 Day – 364 Days
- Safety and efficacy not established age less than 1 year.
Famotidine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Omeprazole
- Severity Level:
2
- Additional Notes: Limited data sug no increased risk for dev tox after 1st trim
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Famotidine
Limited data suggest low amounts excreted, with no resulting effect on infant
Insufficient data available; low levels excreted into breast milk
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest low amounts excreted, with no resulting effect on infant |
Omeprazole
Limited data suggest low amounts excreted, with no resulting effect on infant
Insufficient data available; low levels excreted into breast milk
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Excreted | Not known; no or inclusive data | Insufficient data available; low levels excreted into breast milk |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Famotidine
Neuro/Psych-Avoid in older adults with or at high risk of delirium because of inducing or worsening delirium. Avoid in elderly with dementia or cognitive impairment. Renal-Dose adjustment may be required for CrCL<50 mL/min. to minimize CNS effects (e.g., mental status changes).
General-Prolonged use may dec absorption of Vitamin B-12. Avoid for >8 weeks duration unless for high risk patients (eg. oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett's esophagitis, pathologic hypersecretory condition, or demonstrated need for maint treatment. Musculoskeletal-Inc risk of fracture with high dose or use >1 year. Gastrointestinal-Long term use may be assoc w/ C. difficile or GI malignancy. Pulmonary-Long term use may be assoc w/pneumonia.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | Y | N | N | Y | N | N |
BEERS: Y HEDIS: N STOPP: N
Omeprazole
Neuro/Psych-Avoid in older adults with or at high risk of delirium because of inducing or worsening delirium. Avoid in elderly with dementia or cognitive impairment. Renal-Dose adjustment may be required for CrCL<50 mL/min. to minimize CNS effects (e.g., mental status changes).
General-Prolonged use may dec absorption of Vitamin B-12. Avoid for >8 weeks duration unless for high risk patients (eg. oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett's esophagitis, pathologic hypersecretory condition, or demonstrated need for maint treatment. Musculoskeletal-Inc risk of fracture with high dose or use >1 year. Gastrointestinal-Long term use may be assoc w/ C. difficile or GI malignancy. Pulmonary-Long term use may be assoc w/pneumonia.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | N | N | N | N | Y | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- None
Duodenal ulcer | |
K26 | Duodenal ulcer |
K26.0 | Acute duodenal ulcer with hemorrhage |
K26.1 | Acute duodenal ulcer with perforation |
K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
K26.5 | Chronic or unspecified duodenal ulcer with perforation |
K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
Duodenal ulcer due to h. pylori | |
B96.81 | Helicobacter pylori [h. pylori] as the cause of diseases classified elsewhere |
Dyspepsia | |
K30 | Functional dyspepsia |
Dyspepsia prevention | |
K30 | Functional dyspepsia |
Erosive esophagitis | |
K22.1 | Ulcer of esophagus |
K22.10 | Ulcer of esophagus without bleeding |
K22.11 | Ulcer of esophagus with bleeding |
Gastric hypersecretion with systemic mastocytosis | |
C96.21 | Aggressive systemic mastocytosis |
D47.02 | Systemic mastocytosis |
K31.89 | Other diseases of stomach and duodenum |
Gastric ulcer | |
K25 | Gastric ulcer |
K25.0 | Acute gastric ulcer with hemorrhage |
K25.1 | Acute gastric ulcer with perforation |
K25.2 | Acute gastric ulcer with both hemorrhage and perforation |
K25.3 | Acute gastric ulcer without hemorrhage or perforation |
K25.4 | Chronic or unspecified gastric ulcer with hemorrhage |
K25.5 | Chronic or unspecified gastric ulcer with perforation |
K25.6 | Chronic or unspecified gastric ulcer with both hemorrhage and perforation |
K25.7 | Chronic gastric ulcer without hemorrhage or perforation |
K25.9 | Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
Gastroesophageal reflux disease | |
K21 | Gastro-esophageal reflux disease |
K21.0 | Gastro-esophageal reflux disease with esophagitis |
K21.9 | Gastro-esophageal reflux disease without esophagitis |
Heartburn | |
R12 | Heartburn |
Helicobacter pylori gastritis | |
B96.81 | Helicobacter pylori [h. pylori] as the cause of diseases classified elsewhere |
Maintenance of healing duodenal ulcer | |
K26 | Duodenal ulcer |
K26.0 | Acute duodenal ulcer with hemorrhage |
K26.1 | Acute duodenal ulcer with perforation |
K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
K26.5 | Chronic or unspecified duodenal ulcer with perforation |
K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
Maintenance of healing erosive esophagitis | |
K22.1 | Ulcer of esophagus |
K22.10 | Ulcer of esophagus without bleeding |
K22.11 | Ulcer of esophagus with bleeding |
Multiple endocrine neoplasia | |
E31.2 | Multiple endocrine neoplasia [MEn] syndromes |
E31.20 | Multiple endocrine neoplasia [MEn] syndrome, unspecified |
E31.21 | Multiple endocrine neoplasia [MEn] type I |
E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
Pathological gastric acid hypersecretory condition | |
K31.89 | Other diseases of stomach and duodenum |
Reflux esophagitis | |
K21.0 | Gastro-esophageal reflux disease with esophagitis |
Zollinger-ellison syndrome | |
E16.4 | Increased secretion of gastrin |
0-9 | A-Z |
---|---|
B96.81 | Helicobacter pylori [h. pylori] as the cause of diseases classified elsewhere |
B96.81 | Helicobacter pylori [h. pylori] as the cause of diseases classified elsewhere |
C96.21 | Aggressive systemic mastocytosis |
D47.02 | Systemic mastocytosis |
E16.4 | Increased secretion of gastrin |
E31.2 | Multiple endocrine neoplasia [MEn] syndromes |
E31.20 | Multiple endocrine neoplasia [MEn] syndrome, unspecified |
E31.21 | Multiple endocrine neoplasia [MEn] type I |
E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
K21 | Gastro-esophageal reflux disease |
K21.0 | Gastro-esophageal reflux disease with esophagitis |
K21.0 | Gastro-esophageal reflux disease with esophagitis |
K21.9 | Gastro-esophageal reflux disease without esophagitis |
K22.1 | Ulcer of esophagus |
K22.1 | Ulcer of esophagus |
K22.10 | Ulcer of esophagus without bleeding |
K22.10 | Ulcer of esophagus without bleeding |
K22.11 | Ulcer of esophagus with bleeding |
K22.11 | Ulcer of esophagus with bleeding |
K25 | Gastric ulcer |
K25.0 | Acute gastric ulcer with hemorrhage |
K25.1 | Acute gastric ulcer with perforation |
K25.2 | Acute gastric ulcer with both hemorrhage and perforation |
K25.3 | Acute gastric ulcer without hemorrhage or perforation |
K25.4 | Chronic or unspecified gastric ulcer with hemorrhage |
K25.5 | Chronic or unspecified gastric ulcer with perforation |
K25.6 | Chronic or unspecified gastric ulcer with both hemorrhage and perforation |
K25.7 | Chronic gastric ulcer without hemorrhage or perforation |
K25.9 | Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
K26 | Duodenal ulcer |
K26 | Duodenal ulcer |
K26.0 | Acute duodenal ulcer with hemorrhage |
K26.0 | Acute duodenal ulcer with hemorrhage |
K26.1 | Acute duodenal ulcer with perforation |
K26.1 | Acute duodenal ulcer with perforation |
K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
K26.5 | Chronic or unspecified duodenal ulcer with perforation |
K26.5 | Chronic or unspecified duodenal ulcer with perforation |
K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
K30 | Functional dyspepsia |
K30 | Functional dyspepsia |
K31.89 | Other diseases of stomach and duodenum |
K31.89 | Other diseases of stomach and duodenum |
R12 | Heartburn |